NPPA computed the Retail Price of Levosalbutamol Sulphate IP eq. to Levosalbutamol 0.63 mg Ipratropium Bromide IP eq. to Ipratropium (Anhydrous) 500 mcg for M/s Axa Parenterals Ltd. (Manufacturer) & M/s Mankind Pharma Ltd. (Marketer)

Apr 09, 2026 | by TeamLease RegTech Legal Research Team

Free Legal updates for the week 00


Industry Specific Compliance

The National Pharmaceutical Pricing Authority (NPPA) on April 06, 2026, issued the Computation of Retail Price of Levosalbutamol Sulphate IP eq. to Levosalbutamol 0.63 mg Ipratropium Bromide IP eq. to Ipratropium (Anhydrous) 500 mcg for M/s Axa Parenterals Ltd. (Manufacturer) & M/s Mankind Pharma Ltd. (Marketer).

The following has been stated namely: -

• The Retail Price has been computed based on the data from July 2025

• The Retail Price has been computed for Each Film Coated Tablet Containing Levosalbutamol Sulphate IP eq. to Levosalbutamol 0.63 mg Ipratropium Bromide IP eq. to Ipratropium (Anhydrous) 500 mcg for M/s Axa Parenterals Ltd. (Manufacturer) & M/s Mankind Pharma Ltd. (Marketer)

• The Total MAT is 32,39,49,520

[Notification No. 19(5060)/2026/DP/NPPA/Div.II]


Bookmark

Related Updates



Alternate Text

Get updates on the go on RegUpdate Mobile App.

NEW  ·  AI ASSISTANT